fbpx
All about COVID19 - An initiative from WhiteCoats that brings together updates from top curated resources exclusively for healthcare professionals

A study revealed that severe COVID-19  patients develop detectable T-cell mediated responses about 3 months after the onset of symptoms and the levels of IgG-specific anti-SARS-CoV-2 antibodies decline over time. The current study was designed to evaluate the specificity and durability of anti- SARS-CoV-2 immune responses in 58 COVID-19 recovered patients who had been hospitalized because of severe COVID-19-related complications. ...

A pre-print paper revealed that glycyrrhizin in licorice root neutralizes SARS-CoV-2 in vitro by inhibiting the main protease Mpro. An in-silico simulation study suggested the antiviral activity of glycyrrhizin against SARS-CoV-2. Researchers from Germany analyzed aqueous licorice root extract. Cytotoxicity was determined at 4-time points using Orangu cell counting solution. The licorice root extract exhibited neutralizing effects even at a ...

Coagenix, New York, USA, and Serum Institute, Pune, India have announced the phase of intranasal live attenuated vaccine for COVID-19. COVI-VACC is a single-dose intranasal, live attenuated vaccine against SARS-CoV-2. It was shown to be safe and efficacious in preclinical animal studies. COVI-VAC was developed with Codagenix's Synthetic Attenuated Virus Engineering (SAVE) platform that uses synthetic biology to re-code the ...

A team of researchers from the University of Massachusetts Lowell and California Baptist University has studied how to face masks impact airflow using a computational model. Their findings will likely influence the guidance on mask-wearing and potentially mask design. The computational face mask model was used to predict how masks impact the inhalation and deposition of airborne particles in the ...

According to research published in the journal ESC Heart Failure, patients with acute heart failure nearly double their risk of dying if they have COVID-19 infection. In a single-center study, 283 patients with acute heart failure were analyzed. The 30-day mortality rate of patients with acute heart failure nearly doubled during the pandemic. Two-thirds of the patients had chronic heart ...

A team of researchers from the University of Edinburg found that consistent mask-wearing was associated with positive well-being among their participants. The team recruited 11,000 participants across the UK who completed the CovidLife surveys, which is an initiative set up by the University of Edinburgh to try and measure and understand the impact of the COVID-19 pandemic on the nation's ...

National Institute of Health researchers have isolated a set o promising, tiny antibodies or nanobodies against SARS-CoV-2 produced by a llama. Preliminary results suggest that at least one of these nanobodies called NIH-CoVnb-112 could prevent infections and detect virus particles by grabbing hold of SARS-CoV-2 spike proteins. The nanobody appeared to work equally well in either liquid or aerosol form, ...

RedHill Biopharma has presented phase 2 data on opaganib in COVID-19 patients on supplemental oxygen. Opaganib is a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor. The trial involved 40 subjects and the results concluded that opaganib led to a numerical improvement in the total oxygen requirement. Investigators randomized 40 COVID-19 patients who developed pneumonia and required oxygen to ...

While new vaccines are being approved to stop the spread of COVID-19, medicines are still needed to treat hospitalized patients. Remdesivir is amongst the first and only antiviral agents approved by the USFDA so far for COVID-19. However, researchers at the University of Cincinnati have said that it is being used too indiscriminately when treating patients hospitalized with the virus. ...

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Computational methods can help identify drugs that can be repurposed against SARS-CoV-2. The researchers combined multiple computational techniques that simulate drug-virus interactions from different, complementary perspectives to aid the virtual screening of ...